BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer

被引：14

作者：

Elazezy, Maha ^{[1
]}

Prieske, Katharina ^{[2
,3
]}

Kluwe, Lan ^{[4
]}

Oliveira-Ferrer, Leticia ^{[2
]}

Peine, Sven ^{[5
]}

Mueller, Volkmar ^{[2
]}

Woelber, Linn ^{[2
]}

Schmalfeldt, Barbara ^{[2
]}

Pantel, Klaus ^{[1
]}

Joosse, Simon A. ^{[1
,3
]}

机构：

[1] Univ Med Ctr Hamburg Eppendorf, Dept Tumor Biol, Martinistr 52, D-20246 Hamburg, Germany

[2] Univ Med Ctr Hamburg Eppendorf, Dept Gynecol & Gynecol Oncol, Hamburg, Germany

[3] Univ Med Ctr Hamburg Eppendorf, Mildred Scheel Canc Career Ctr HaTriCS4, Hamburg, Germany

[4] Univ Med Ctr Hamburg Eppendorf, Dept Oral & Maxillofacial Surg, Hamburg, Germany

[5] Univ Med Ctr Hamburg Eppendorf, Dept Transfus Med, Hamburg, Germany

来源：

MOLECULAR ONCOLOGY | 2021年 / 15卷 / 12期

关键词：

BRCA1; ctDNA; liquid biopsy; MS-qPCR; SPORADIC BREAST; LIQUID BIOPSY; METHYLATION; QUANTIFICATION; FREQUENCY; MUTATIONS; REGION; PLASMA;

D O I：

10.1002/1878-0261.13108

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Methylation of the BRCA1 promoter is an epigenetic gene expression regulator and is frequently observed in ovarian cancer; however, conversion of methylation status is thought to drive disease recurrence. Therefore, longitudinal monitoring of methylation status by liquid biopsy in cell-free DNA may be a predictive marker. In total, 135 plasma samples were collected from 69 ovarian cancer patients before and during systemic treatment. Our liquid biopsy assay could detect down to a single molecule of methylated DNA in a high background of normal DNA (0.03%) with perfect specificity in control samples. We found that 60% of the cancer patients exhibited BRCA1 promoter hypermethylation at one point, although 24% lost hypermethylation during treatment. Multivariate survival analyses indicate that relapses are independent events and that hypermethylation and methylation conversion are independently correlated to longer relapse-free survival. We present a highly sensitive and specific methylation-specific quantitative PCR-based liquid biopsy assay. BRCA1 promoter hypermethylation is frequently found in ovarian cancer and is often reversed upon recurrence, indicating the selection of therapy-resistant clones and unfavorable clinical outcome.

引用

页码：3615 / 3625

页数：11

共 34 条

[1] Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer [J].

Abkevich, V. ;

Timms, K. M. ;

Hennessy, B. T. ;

Potter, J. ;

Carey, M. S. ;

Meyer, L. A. ;

Smith-McCune, K. ;

Broaddus, R. ;

Lu, K. H. ;

Chen, J. ;

Tran, T. V. ;

Williams, D. ;

Iliev, D. ;

Jammulapati, S. ;

FitzGerald, L. M. ;

Krivak, T. ;

DeLoia, J. A. ;

Gutin, A. ;

Mills, G. B. ;

Lanchbury, J. S. .

BRITISH JOURNAL OF CANCER, 2012, 107 (10) :1776-1782

[2] Modelling recurrent events: a tutorial for analysis in epidemiology [J].

Amorim, Leila D. A. F. ;

Cai, Jianwen .

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2015, 44 (01) :324-333

[3]

Baldwin RL, 2000, CANCER RES, V60, P5329

[4] Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[5]

Capizzi E, 2008, DIAGN MOL PATHOL, V17, P34, DOI 10.1097/PDM.0b013e3181359e1f

[6] Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer:: correlation with disease characteristics [J].

Catteau, A ;

Harris, WH ;

Xu, CF ;

Solomon, E .

ONCOGENE, 1999, 18 (11) :1957-1965

[7] Survival analysis part IV: Further concepts and methods in survival analysis [J].

Clark, TG ;

Bradburn, MJ ;

Love, SB ;

Altman, DG .

BRITISH JOURNAL OF CANCER, 2003, 89 (05) :781-786

[8]

Dobrovic A, 1997, CANCER RES, V57, P3347

[9] Circulating cell-free DNA (cfDNA) levels in BRCA1 and BRCA2 mutation carriers: A preliminary study [J].

Douvdevani, Amos ;

Bernstein-Molho, Rinat ;

Asraf, Keren ;

Doolman, Ram ;

Laitman, Yael ;

Friedman, Eitan .

CANCER BIOMARKERS, 2020, 28 (03) :269-273

[10] Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management [J].

Elazezy, Maha ;

Joosse, Simon A. .

COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2018, 16 :370-378

← 1 2 3 4 →